← Back
Data updated: Jun 28, 2026
RECORDATI RARE
Big Pharma Pharmaceuticals
RECORDATI RARE is a major pharmaceutical company with 12 FDA-approved products.
1949
Since
12
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
8 Small Molecules
FDA Novel Drug Designations
(2020) 1 Novel 1 First-in-Class 1 Orphan
See 1 novel approval →
RECORDATI RARE's Key Drugs
RECORDATI RARE's core commercial portfolio centers on CYSTADROPS, ISTURISA, SIGNIFOR — its most strategically important drugs approved in the last 15 years.
RECORDATI RARE's Recent FDA Approvals
New NDA/BLA approvals for RECORDATI RARE over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
RECORDATI RARE's Therapeutic Areas
Disease areas where RECORDATI RARE has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
RECORDATI RARE Pipeline Snapshot
Active clinical trials for RECORDATI RARE across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 1949-03-15
- Latest
- 2025-11-04
- Applications
- 12